Research
1. Yasin I, Stengel A, Shao H, et al. Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study. Cancer 2026;132:e70210. doi:10.1002/cncr.70210.
2. Watts J, Madarang E, Abbott D, et al. Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy. Haematologica 2026. doi:10.3324/haematol.2025.300374.
3. Bulterys P, Zhou CW, Gong S, et al. Clinicopathologic and Molecular Characteristics of Merkel Cell Polyomavirus Positive T-Cell Lymphoproliferative Disorders. Am J Surg Pathol 2026;50:481–500. doi:10.1097/PAS.0000000000002521.
4. Zhang J, Bulterys PL, Fernandez-Pol S, et al. Expression of CD47 protein in hematolymphoid neoplasms: Implications for CD47-mediated cancer immunotherapy. Am J Clin Pathol 2025;163:883–897. doi:10.1093/ajcp/aqaf018.
5. Pollyea DA, Stevens BM, Abbott D, et al. Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial. EClinicalMedicine 2025;89:103546. doi:10.1016/j.eclinm.2025.103546.
6. Pandiri M, Stengel A, Zhang J, et al. Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study. J Clin Pathol 2025;78:629–635. doi:10.1136/jcp-2024-209954.
7. Islam N, Dale JL, Reuben JS, et al. Development of a Dynamic Counterfactual Risk Stratification Strategy for Newly Diagnosed Patients With AML Treated With Venetoclax and Azacitidine. JCO Clin Cancer Inform 2025;9:e2400308. doi:10.1200/CCI-24-00308.
8. Gisriel SD, Yuan J, Tang H, et al. Concurrent or subsequent lymphomatous effusion in large B-cell lymphoma portends a dismal prognosis: A multi-institutional study. Am J Clin Pathol 2025;164:390–401. doi:10.1093/ajcp/aqaf057.
9. Gilbert JS, Connor M, Bosma G, et al. Known Prognostic Models Fail to Predict Outcomes for Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Retrospective Analysis. Am J Hematol 2025;100:2140–2143. doi:10.1002/ajh.70034.
10. Alnoor F, Spies NC, Kumar J, et al. The Evolution and Recent Advances in Diagnostic Criteria for Idiopathic Multicentric Castleman Disease. Am J Hematol 2025;100:2064–2073. doi:10.1002/ajh.70039.
11. Zhou X, Zhang J. EBV-positive inflammatory follicular dendritic cell sarcoma, an entity by many names. British Journal of Haematology 2024;n/a. doi:10.1111/bjh.19891.
12. Wadsworth P, Zhang J, Miller T, et al. Prevalence and clinicopathological features of incidentally detected TRBC1-dim populations in peripheral blood flow cytometry. Leuk Lymphoma 2024:1–4. doi:10.1080/10428194.2024.2354527.
13. Symes EO, Wang P, Sojitra P, et al. Somatic co-alteration signatures are prognostic in high-grade -mutated myeloid neoplasms. British Journal of Haematology 2024;n/a. doi:10.1111/bjh.19895.
14. Zhang J, Tan B, Fernandez-Pol S. Lupus erythematosus cells in a bone marrow aspirate. Journal of Hematopathology 2023;16:247–248. doi:10.1007/s12308-023-00561-8.
15. Zhang J, Oak J. Challenges of detecting measurable/minimal disease in acute leukemia. Seminars in Diagnostic Pathology 2023;40:216–220. doi:10.1053/j.semdp.2023.04.004.
16. Zhang J, Fernandez-Pol S. TRBC1 enables identification of an otherwise immunophenotypically silent case of angioimmunoblastic T-cell lymphoma. Journal of Hematopathology 2023;16:59–61. doi:10.1007/s12308-023-00533-y.
17. Zhang J, Tan B. Gelatinous transformation of the bone marrow in a previously healthy male presenting with pancytopenia. British Journal of Haematology 2022;197:7.
18. Wang H, Zhang J, Kao C-S, et al. Photo Quiz: A 25-Year-Old Man with Hematuria and a Bladder Nodule. J Clin Microbiol 2022;60:e0124621. doi:10.1128/jcm.01246-21.
19. Koo M, Zhang J, Tan B, et al. Human Germinal Center–associated Lymphoma (HGAL) Is a Reliable Marker of Normal and Neoplastic Follicular Helper T Cells Including Angioimmunoblastic T-Cell Lymphoma. The American Journal of Surgical Pathology 2022;46:643–654.
20. Brown RA, Wang JY, Raghavan SS, et al. ALK‐positive compound Spitz nevus with extensive perineural and intraneural neurotropism. Journal of Cutaneous Pathology 2021;48:154–159.
21. Harsha Krovi S, Zhang J, Michaels-Foster MJ, et al. Thymic iNKT single cell analyses unmask the common developmental program of mouse innate T cells. Nature Communications 2020;11:1–15.
22. Tuttle KD, Krovi SH, Zhang J, et al. TCR signal strength controls thymic differentiation of iNKT cell subsets. Nature Communications 2018;9:1–13.
23. Sundararaj S, Zhang J, Krovi SH, et al. Differing roles of CD1d2 and CD1d1 proteins in type I natural killer T cell development and function. Proceedings of the National Academy of Sciences 2018;115:E1204–E1213.
24. Zhang J, Bedel R, Krovi SH, et al. Mutation of the Traj18 gene segment using TALENs to generate natural killer T cell deficient mice. Scientific Reports 2016;6:1–10.
25. Williams JA, Zhang J, Jeon H, et al. Thymic medullary epithelium and thymocyte self-tolerance require cooperation between CD28–CD80/86 and CD40–CD40L costimulatory pathways. The Journal of Immunology 2014;192:630–640.
26. Bedel R, Berry R, Mallevaey T, et al. Effective functional maturation of invariant natural killer T cells is constrained by negative selection and T-cell antigen receptor affinity. Proceedings of the National Academy of Sciences 2014;111:E119–E128.
27. Jenkinson SR, Williams JA, Jeon H, et al. TRAF3 enforces the requirement for T cell cross-talk in thymic medullary epithelial development. Proceedings of the National Academy of Sciences 2013;110:21107–21112.
28. Patel O, Pellicci DG, Uldrich AP, et al. Vβ2 natural killer T cell antigen receptor-mediated recognition of CD1d-glycolipid antigen. Proceedings of the National Academy of Sciences 2011;108:19007–19012.
29. Williams JA, Lumsden JM, Yu X, et al. Regulation of thymic NKT cell development by the B7-CD28 costimulatory pathway. The Journal of Immunology 2008;181:907–917.
